Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

AstraZeneca
Moodys
Baxter
Medtronic
Merck
Boehringer Ingelheim

Last Updated: December 3, 2022

CLINICAL TRIALS PROFILE FOR JAKAFI


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Jakafi

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01251965 ↗ Phase l/II Study of Ruxolitinib for Acute Leukemia Terminated Incyte Corporation Phase 1/Phase 2 2010-12-01 The goal of this clinical research study is to find the highest tolerable dose of ruxolitinib that can be given to patients with acute leukemia and to learn if the study drug can help control the disease. The safety of the drug will also be studied.
NCT01251965 ↗ Phase l/II Study of Ruxolitinib for Acute Leukemia Terminated M.D. Anderson Cancer Center Phase 1/Phase 2 2010-12-01 The goal of this clinical research study is to find the highest tolerable dose of ruxolitinib that can be given to patients with acute leukemia and to learn if the study drug can help control the disease. The safety of the drug will also be studied.
NCT01431209 ↗ Ruxolitinib Phosphate in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell or Peripheral T-Cell Non-Hodgkin Lymphoma After Donor Stem Cell Transplant Completed Incyte Corporation Phase 2 2011-08-01 This phase II trial studies how well ruxolitinib phosphate works in treating patients with diffuse large B-cell or peripheral T-cell non-Hodgkin lymphoma that has returned (relapsed) or that does not respond to treatment (refractory) after donor stem cell transplant. Ruxolitinib phosphate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
NCT01431209 ↗ Ruxolitinib Phosphate in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell or Peripheral T-Cell Non-Hodgkin Lymphoma After Donor Stem Cell Transplant Completed National Cancer Institute (NCI) Phase 2 2011-08-01 This phase II trial studies how well ruxolitinib phosphate works in treating patients with diffuse large B-cell or peripheral T-cell non-Hodgkin lymphoma that has returned (relapsed) or that does not respond to treatment (refractory) after donor stem cell transplant. Ruxolitinib phosphate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Jakafi

Condition Name

Condition Name for Jakafi
Intervention Trials
Myelofibrosis 16
Primary Myelofibrosis 14
Leukemia 8
Essential Thrombocythemia 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Jakafi
Intervention Trials
Primary Myelofibrosis 26
Leukemia 20
Thrombocytosis 14
Thrombocythemia, Essential 13
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Jakafi

Trials by Country

Trials by Country for Jakafi
Location Trials
United States 386
Italy 19
Japan 14
Spain 13
China 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Jakafi
Location Trials
Texas 35
New York 20
North Carolina 18
California 17
Oregon 17
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Jakafi

Clinical Trial Phase

Clinical Trial Phase for Jakafi
Clinical Trial Phase Trials
Phase 4 1
Phase 3 7
Phase 2/Phase 3 1
[disabled in preview] 36
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Jakafi
Clinical Trial Phase Trials
Recruiting 35
Completed 15
Active, not recruiting 7
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Jakafi

Sponsor Name

Sponsor Name for Jakafi
Sponsor Trials
Incyte Corporation 34
National Cancer Institute (NCI) 27
M.D. Anderson Cancer Center 11
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Jakafi
Sponsor Trials
Other 79
Industry 57
NIH 30
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Boehringer Ingelheim
Moodys
Johnson and Johnson
Baxter
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.